Abstract: Disclosed are peptides which specifically bind to preselected pre-miRNA or pri-miRNA targets, methods of down-regulating EMT in a cell using such peptides, and methods of preparing such peptides. Also provided are therapeutic compositions comprising peptides that specifically bind a preselected cancer marker which is a peptide or which is a pre-miRNA or a pri-miRNA and methods of treatment using the same.

Abstract: Provided herein are methods to generate and screen peptides that exhibit drug like stabilities in vitro and in vivo. By selecting for enzyme resistance, Applicants are able to derive peptides that are not only stable to a broad spectrum of proteases, but also stable to other drug processing enzymes such as cytochrome P450s. This approach provides a general method to the rapid development of highly stable peptides for therapeutic development and diagnosis. The peptides are further modified for oral bioavailability.

Abstract: Provided herein are methods to generate and screen peptides that exhibit drug like stabilities in vitro and in vivo. By selecting for enzyme resistance, Applicants are able to derive peptides that are not only stable to a broad spectrum of proteases, but also stable to other drug processing enzymes such as cytochrome P450s. This approach provides a general method to the rapid development of highly stable peptides for therapeutic development and diagnosis. The peptides are further modified for oral bioavailability. The methods can be applied to similar peptides for the making of therapeutic compositions.

Abstract: Disclosed are peptide-mRNA fusion products, oligoribonucleotide structures, and methods of producing and using the same.

Abstract: Disclosed are peptides which specifically bind to preselected pre-miRNA or pri-miRNA targets, methods of down-regulating EMT in a cell using such peptides, and methods of preparing such peptides. Also provided are therapeutic compositions comprising peptides that specifically bind a preselected cancer marker which is a peptide or which is a pre-miRNA or a pri-miRNA and methods of treatment using the same.

Abstract: The present disclosure describes a method enabling the engineering of ligands with sub-nanomolar dissociation constants via a process of selection and extension (“extension selection”).

Abstract: Provided herein are methods to generate and screen peptides that exhibit drug like stabilities in vitro and in vivo. By selecting for enzyme resistance, Applicants are able to derive peptides that are not only stable to a broad spectrum of proteases, but also stable to other drug processing enzymes such as cytochrome P450s. This approach provides a general method to the rapid development of highly stable peptides for therapeutic development and diagnosis. The peptides are further modified for oral bioavailability.